Ginkgo Bioworks Holdings (DNA) EBT (2020 - 2026)

Ginkgo Bioworks Holdings has reported EBT for 7 years, with the latest figure at -$76.1 million in Q1 2026.

• For the quarter ending Q1 2026, EBT rose 8.51% year-over-year to -$76.1 million; the trailing twelve-month figure through Mar 2026 stood at -$298.9 million (up 35.71% YoY), and the FY2025 full-year result was -$313.6 million, up 42.72% from the prior year.
• EBT for Q1 2026 stood at -$76.1 million, up from -$81.4 million in the prior quarter.
• The five-year high for EBT was -$56.8 million in Q3 2024, with the low at -$670.6 million in Q2 2022.
• Historically, EBT has averaged -$232.0 million across 5 years, with a median of -$173.2 million in 2023.
• The largest YoY upside for EBT was 88.3% in 2022 against a maximum downside of 1121.63% in 2022.
• Ginkgo Bioworks Holdings' EBT stood at -$187.8 million in 2022, then fell by 12.8% to -$211.9 million in 2023, then soared by 49.1% to -$107.9 million in 2024, then increased by 24.54% to -$81.4 million in 2025, then gained by 6.46% to -$76.1 million in 2026.
• The last three EBT figures came in at -$76.1 million (Q1 2026), -$81.4 million (Q4 2025), and -$80.8 million (Q3 2025), per Business Quant data.